Waystar vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Waystar is a healthcare payments and revenue cycle technology platform processing over $5 trillion in claims annually for hospitals, health systems, and physician groups.
About
Waystar is a healthcare technology company formed through the 2019 merger of ZirMed and Navicure that provides cloud-based revenue cycle management technology to healthcare providers. The platform automates the complex workflows involved in healthcare payments including eligibility verification, claims submission, denial management, payment posting, and patient payment collection. Waystar processes over $5 trillion in annual claims for a network of over 1,000 health plan and payer connections, making it one of the largest healthcare clearinghouse and RCM technology providers in the United States. The company serves hospitals, health systems, physician practices, and ancillary care providers of all sizes through a SaaS platform that integrates with major EHR systems. Waystar went public on Nasdaq in 2024 following years of private equity ownership under EQT Partners. The company uses AI to improve claim accuracy before submission, prioritize denial appeals, and automate patient payment workflows. Waystar's scale and network of payer connections make it a critical piece of healthcare financial infrastructure for providers seeking to improve cash flow and reduce administrative costs.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.